VALGANCICLOVIR

Valganciclovir is an antiviral medication used to treat infections caused by cytomegalovirus (CMV) in patients who have received organ transplants or have acquired immunodeficiency syndrome (AIDS).

Indications

-Prevention of CMV disease in organ transplant recipients. -Treatment of CMV retinitis in patients with AIDS.

Dosage

-Adults: The dosage varies based on the condition being treated and the patient's renal function. For CMV retinitis, the usual dose is 900 mg twice daily for 21 days, followed by 900 mg once daily. -Pediatric Patients: Dosing is determined based on weight and clinical condition.

Contra-Indications

-Hypersensitivity to valganciclovir or ganciclovir. -Pregnant or breastfeeding women (unless the potential benefits outweigh the risks).

Special Precautions

-Monitor blood counts regularly as valganciclovir can cause bone marrow suppression. -Adjust dosage in cases of renal impairment. -Use effective contraception during and after treatment due to potential teratogenic effects.

Side Effects

-Common: Nausea, diarrhea, headache, and insomnia. -Serious: Bone marrow suppression, including neutropenia and thrombocytopenia, and renal impairment.

Drug Interactions

-Probenecid: May increase the risk of valganciclovir toxicity. -Other myelosuppressive agents: Can enhance the risk of bone marrow suppression. -Zidovudine: May increase the risk of hematologic adverse effects.